new recommendations from its expert panel on selective COX-2 NSAIDs
August 2005
Health Canada will now consider new recommendations from its expert panel on selective COX-2 NSAIDs.
This is the first time the public has been asked to sit on an expert advisory panel...along with rheumatologists, internists, etc.
The panel recommends that Celebrex remain on the market...and that Vioxx be allowed to RETURN to the market.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive